{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:48:05Z","timestamp":1774003685228,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.xphs.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T01:28:16Z","timestamp":1479346096000},"page":"560-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole"],"prefix":"10.1016","volume":"106","author":[{"given":"Rodrigo","family":"Cristofoletti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikunjkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2016.10.008_bib1","series-title":"Der Blutspiegel Kinetik der Konzentrationsabl\u00e4ufe in der Kreislauffl\u00fcssigkeit","first-page":"362","author":"Dost","year":"1953"},{"key":"10.1016\/j.xphs.2016.10.008_bib2","first-page":"205","article-title":"Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration","volume":"57","author":"Teorell","year":"1937","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.xphs.2016.10.008_bib3","first-page":"226","article-title":"Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration","volume":"57","author":"Teorell","year":"1937","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.xphs.2016.10.008_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01059734","article-title":"A\u00a0review of the applications of physiologically based pharmacokinetic modeling","volume":"7","author":"Himmelstein","year":"1979","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009739509178895","article-title":"Torsten Teorell, the father of pharmacokinetics","volume":"100","author":"Paalzow","year":"1995","journal-title":"Ups J Med Sci"},{"issue":"6","key":"10.1016\/j.xphs.2016.10.008_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2005.02560.x","article-title":"Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed","volume":"60","author":"Aarons","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2016.10.008_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0163-7258(81)90097-8","article-title":"History of pharmacokinetics","volume":"12","author":"Wagner","year":"1981","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.xphs.2016.10.008_bib8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jps.2600570814","article-title":"Thiopental pharmacokinetics","volume":"57","author":"Bischoff","year":"1968","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jps.2600600803","article-title":"Methotrexate pharmacokinetics","volume":"60","author":"Bischoff","year":"1971","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.xphs.2016.10.008_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0041-008X(83)90323-X","article-title":"Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species","volume":"67","author":"King","year":"1983","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1-3","key":"10.1016\/j.xphs.2016.10.008_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-4274(95)03355-O","article-title":"Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment","volume":"79","author":"Andersen","year":"1995","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.xphs.2016.10.008_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/978-1-4614-3055-1_6","article-title":"Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment","volume":"745","author":"Lipscomb","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.xphs.2016.10.008_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jps.2600730922","article-title":"Physicochemical model for dose-dependent drug absorption","volume":"73","author":"Dressman","year":"1984","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jps.2600750202","article-title":"Mixing-tank model for predicting dissolution rate control or oral absorption","volume":"75","author":"Dressman","year":"1986","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental transit and dispersion model\u00a0analysis of small intestinal transit flow in humans","volume":"140","author":"Yu","year":"1996","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E","article-title":"A\u00a0priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery","volume":"89","author":"Poulin","year":"2000","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2016.10.008_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically based pharmacokinetics joined with in\u00a0vitro-in\u00a0vivo extrapolation of ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2016.10.008_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in\u00a0vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2016.10.008_bib25","unstructured":"U.S. Food and Drug Administration. Program of physiologically-based pharmacokinetic and pharmacodynamic modeling (PBPK Program). Available at: http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm365118.htm. Accessed July 29,\u00a02016."},{"key":"10.1016\/j.xphs.2016.10.008_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2008.144","article-title":"Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice","volume":"84","author":"Huang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.xphs.2016.10.008_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003088-199121010-00004","article-title":"Clinical pharmacokinetics in patients with liver disease","volume":"21","author":"McLean","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2016.10.008_bib29","series-title":"Guideline on investigation of bioequivalence","year":"2010"},{"key":"10.1016\/j.xphs.2016.10.008_bib30","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.xphs.2016.01.027","article-title":"Exploratory investigation of the limiting steps of oral absorption of fluconazole and ketoconazole in children using an in silico pediatric absorption model","volume":"105","author":"Cristofoletti","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1208\/s12248-016-9885-2","article-title":"Pediatric biopharmaceutical classification system: using age-appropriate initial gastric volume","volume":"18","author":"Shawahna","year":"2016","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.xphs.2016.10.008_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.7326\/0003-4819-109-6-471","article-title":"Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)","volume":"109","author":"Lake-Bakaar","year":"1988","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.xphs.2016.10.008_bib33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/gast.1996.v110.pm8612992","article-title":"Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study","volume":"110","author":"Feldman","year":"1996","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1248\/bpb.24.313","article-title":"Assessment of gastric acidity of Japanese subjects over the last 15 years","volume":"24","author":"Morihara","year":"2001","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.xphs.2016.10.008_bib36","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","article-title":"Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.xphs.2016.10.008_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.xphs.2016.10.008_bib38","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1021\/mp200062a","article-title":"Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect","volume":"8","author":"Mitra","year":"2011","journal-title":"Mol Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2016.10.008_bib39","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.xphs.2015.11.033","article-title":"Different magnitude of positive food effects for two weak bases with similar BCS drug-related properties: what\u00a0is happening in the intestinal lumen?","volume":"105","author":"Cristofoletti","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2016.10.008_bib40","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2016.10.008_bib41","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2016.10.008_bib42","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11095-006-9209-9","article-title":"Estimation of\u00a0intragastric solubility of drugs: in what medium?","volume":"24","author":"Vertzoni","year":"2007","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2016.10.008_bib44","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.10.008_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0939-6411(00)00113-2","article-title":"Effect of solubilizing excipients on permeation of poorly water soluble compounds across Caco-2 cell monolayers","volume":"50","author":"Saha","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.10.008_bib47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A\u00a0review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib48","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.04223-14","article-title":"Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2016.10.008_bib50","series-title":"Antifungal Composition with Enhanced Bioavailability. U.S. Patent 8263600","author":"Sharpe","year":"2012"},{"key":"10.1016\/j.xphs.2016.10.008_bib51","series-title":"Scientific Discussion: Noxafil (Posaconazole)","year":"2005"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11095-009-0036-7","article-title":"Leakiness and size exclusion of paracellular channels in cultured epithelial cell monolayers\u2014interlaboratory comparison","volume":"27","author":"Avdeef","year":"2010","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1015970502993","article-title":"Dissolution of ionizable drugs in buffered and unbuffered solutions","volume":"5","author":"Ozturk","year":"1988","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2016.10.008_bib54","first-page":"1106","article-title":"The effect of meal energy content on gastric emptying","volume":"30","author":"Velchik","year":"1989","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.25.1.1","article-title":"Influence of food on the pharmacokinetics of ketoconazole","volume":"25","author":"Daneshmend","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib56","first-page":"e150","article-title":"Physiologically based pharmacokinetic modeling and simulation in pediatric drug development","volume":"22","author":"Maharaj","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ed060p420","article-title":"Determination of phosphoric acid in cola beverages: a colorimetric and pH titration experiment for general chemistry","volume":"60","author":"Murphy","year":"1983","journal-title":"J\u00a0Chem Educ"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0016-5085(83)80232-7","article-title":"Regulation of the gastric emptying of glucose","volume":"85","author":"Brener","year":"1983","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.xphs.2016.10.008_bib59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/03639040601031882","article-title":"Preparation, characterization, and scale-up of ketoconazole with enhanced dissolution and bioavailability","volume":"33","author":"Elder","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2016.10.008_bib61","series-title":"Committee for Medicinal Products for Human Use (CHMP), Assessment Report: Procedure No. EMEA\/H\/C\/003906\/0000","year":"2014"},{"issue":"11","key":"10.1016\/j.xphs.2016.10.008_bib62","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jps.2600700103","article-title":"Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions","volume":"70","author":"Mooney","year":"1981","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jps.2600740209","article-title":"Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts. II. Salicylic acid, theophylline, and benzoic acid","volume":"74","author":"Serajuddin","year":"1985","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib65","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.21.5.730","article-title":"Impairing effect of food on ketoconazole absorption","volume":"21","author":"M\u00e4nnist\u00f6","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib66","first-page":"228","article-title":"Effect of food and gastric acidity on\u00a0absorption of orally administered ketoconazole","volume":"7","author":"Lelawongs","year":"1988","journal-title":"Clin Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2016.10.008_bib68","first-page":"1334","article-title":"Effect of pH on disintegration and dissolution of ketoconazole tablets","volume":"40","author":"Carlson","year":"1983","journal-title":"Am J Hosp Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2016.10.008_bib69","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1021\/mp400283j","article-title":"Investigation of the rat model for preclinical evaluation of pH-dependent oral absorption in humans","volume":"10","author":"Lubach","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2016.10.008_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejps.2015.05.015","article-title":"Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers","volume":"76","author":"Adachi","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib71","series-title":"The Effects of Two Gastric Acidifying Agents on the Pharmacokinetics of Ketoconazole","author":"Sutherland","year":"1983"},{"issue":"9","key":"10.1016\/j.xphs.2016.10.008_bib72","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1177\/0091270003255645","article-title":"Gastric function in the elderly: effects on absorption of ketoconazole","volume":"43","author":"Hurwitz","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1113\/jphysiol.1969.sp008749","article-title":"The slowing of gastric emptying by nine acids","volume":"201","author":"Hunt","year":"1969","journal-title":"J\u00a0Physiol"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.10.008_bib74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(01)00795-5","article-title":"The effect of pH change on the gastric emptying of liquids measured by electrical impedance tomography and pH-sensitive radiotelemetry capsule","volume":"227","author":"Chaw","year":"2001","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2016.10.008_bib75","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejps.2011.04.016","article-title":"Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids","volume":"43","author":"Clarysse","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.10.008_bib76","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2016","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.xphs.2016.10.008_bib77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/j.1875-9114.1993.tb02743.x","article-title":"Differences in serum concentration of and responses to generic verapamil in the elderly","volume":"13","author":"Carter","year":"1993","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.xphs.2016.10.008_bib78","first-page":"511","article-title":"Kinetics and dynamics of single doses of oxazepam in the elderly: implications of absorption rate","volume":"47","author":"Dreyfuss","year":"1986","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.xphs.2016.10.008_bib79","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/009286159502900303","article-title":"Current scientific issues regarding bioavailability\/bioequivalence studies: an academic view","volume":"29","author":"Meyer","year":"1995","journal-title":"Drug Inf J"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib80","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s11095-006-9899-z","article-title":"Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389","volume":"23","author":"Badawy","year":"2006","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.10.008_bib81","doi-asserted-by":"crossref","first-page":"844","DOI":"10.18433\/J36P5M","article-title":"When bioequivalence in healthy volunteers may not translate to bioequivalence in\u00a0patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets","volume":"18","author":"Yue","year":"2015","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1018952415732","article-title":"Kinetics of degradation of levothyroxine in aqueous solution and in solid state","volume":"9","author":"Won","year":"1992","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib83","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1208\/s12249-011-9660-8","article-title":"An investigation into the influence of experimental conditions on in\u00a0vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability","volume":"12","author":"Kocic","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2016.10.008_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/FTD.0b013e318217b69f","article-title":"Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions","volume":"33","author":"Colucci","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.xphs.2016.10.008_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12020-014-0476-7","article-title":"Thyroxine softgel capsule in patients with gastric-related T4 malabsorption","volume":"49","author":"Santaguida","year":"2015","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.xphs.2016.10.008_bib86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5414\/CPP46055","article-title":"Rapidly dissolving formulations for quick absorption during pain episodes: ibuprofen","volume":"46","author":"Jamali","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2016.10.008_bib87","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ejpb.2008.07.013","article-title":"Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations","volume":"70","author":"Aghazadeh-Habashi","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.10.008_bib88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpb.2015.12.004","article-title":"Disease specific modeling: simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions","volume":"100","author":"Almukainzi","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.10.008_bib89","series-title":"Ketoconazole SmPC","year":"2016"},{"key":"10.1016\/j.xphs.2016.10.008_bib90","series-title":"Ketoconazole SmPC","year":"2016"},{"key":"10.1016\/j.xphs.2016.10.008_bib91","series-title":"Ketoconazole SmPC","year":"2016"},{"key":"10.1016\/j.xphs.2016.10.008_bib92","series-title":"Posaconazole SmPC","year":"2016"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916417831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916417831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:00:37Z","timestamp":1718902837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916417831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0022354916417831"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.10.008","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}